由于中国政府重申扶持和促进中医药产业的发展，中医药制造商正在大规模拓展全球市场。
据公司相关负责人表示，我国最大的特许制药商广州白云山医药集团将设立2亿元（约合3千万美元）基金，用于在未来5年内拓展中医药海外市场。
广州白云山医药集团副总经理王文楚表示，这项基金将主要用于中医药产业海外注册，全球市场运作以及国际合作。
上海挂牌公司在上个月与一家尼日利亚公司签署了合作协议，这为之后的发展取得了良好的开端。
据北京同仁堂(集团)有限责任公司副总经理丁永玲表示，这家老字号的中药生产商，也正在扩大其全球影响力。
丁永玲说，同仁堂已经在全球25个国家和地区开设了115家药店，另外，该公司可能还会考虑在海外市场收购更多的本地药店、诊所以及其他传统中医药公司。
全国人大常委会正在审议我国首部《中医药法(草案)》，随后政府作出了扶持中医药产业发展的最新承诺。国联证券分析师刘生平表示，该法将有助于中医药企业为全球范围内的患者提供更多产品。
不过，由于文化和政策差异，中医药企业走向国际化仍会面临一些挑战。（中国进出口网）
Traditional Chinese medicine (TCM) makers are expanding their presence in the global markets in a big way, as the government reiterated its support to further strengthen the sector.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, the largest patent drugmaker in China, is setting up a 200 million yuan ($30.87 million) fund to expand its overseas TCM presence in the next five years, according to company officials.
The fund will be mainly used for the overseas registration of TCM products, global market operations and international cooperation, said Wang Wenchu, deputy general manager of Guangzhou Baiyunshan.
The Shanghai-listed company has already made a good start by signing a cooperation agreement with a Nigerian company last month.
Beijing Tong Ren Tang Group Co Ltd, a time-honored TCM producer, is also expanding its global presence, said Ding Yongling, deputy general manager of group.
Tong Ren Tang already runs 115 medicine stores in 25 countries and regions, said Ding, adding that the company may consider more acquisitions in overseas markets like local medicine stores, clinics and other TCM companies.
The latest support commitment from the government comes close on the heels of the draft of China's first TCM law being discussed by the Standing Committee of the National People's Congress. The law will help TCM companies provide more products to patients globally, said Liu Shengping, an analyst from Guolian Securities.
But there are still some challenges for China's TCM firms to go global because of the cultural and policy differences.
